Commonly used indicators of sepsis are nonspecific and insufficient for predicting the course of febrile neutropenia (FN) in hematological patients. We analyzed data from 91 adult FN patients who received intensive chemotherapy for acute myeloid leukemia or autologous stem cell transplantation. Compared to patients with non-severe sepsis, patients with severe sepsis had significantly higher serum levels of tissue inhibitor of metalloproteinases-1 on the day of first occurrence of fever (day 0: 172 vs. 112 µg/L, p= .002) and for the two following days (day 1: 219 vs. 128 µg/L, p< .001; day 2: 443 vs. 128 µg/L, p= .001), and significantly higher serum levels of matrix metalloproteinase-10 on day 1 (1975 vs. 876 ng/L, p= .001) and day 2 (2020 vs. 841 ng/L, p< .001). We conclude that the measurement of these biomarkers may be useful in predicting the severity of sepsis in FN patients.
Febrile neutropenia (FN) is a common complication of chemotherapy and potentially fatal. It is often associated with mucositis. Timely recognition of complications enables early supportive treatment and potentially reduces mortality. Common diagnostic parameters are often nonspecific or have slow kinetics. This study examines the applicability of mucosa-related biomarkers in the recognition of complicated course among 78 adult hematologic patients with FN after intensive chemotherapy. Plasma concentrations of citrulline, intestinal fatty acid binding protein (I-FABP), zonula occludens-1 (ZO-1) and alpha-1 acid glycoprotein (α1AGP), as well as C-reactive protein (CRP) and procalcitonin (PCT), were measured at the onset of fever and the following two days. All except ZO-1 showed a significant trend. Concentrations of CRP, PCT, citrulline and α1AGP were higher with a complicated course. Patients with severe sepsis had higher levels of PCT and lower levels of I-FABP. In conclusion, measurement of mucosa-related biomarkers might help predict the course of FN.